^
    Apply
    A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (NCT04539496)
    Phase 1/2
    Sihuan Pharmaceutical Holdings Group Ltd.
    Active, not recruiting
    Last update posted :
    09/13/2024
    Initiation :
    05/22/2018
    Primary completion :
    07/31/2023
    Completion :
    12/31/2025
    HER-2
    |
    HR positive • HER-2 negative
    |
    fulvestrant • letrozole • anastrozole • bireociclib (XZP 3287)
    A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer (BRIGHT-2) (NCT05077449)
    Phase 3
    Xuanzhu Biopharmaceutical Co., Ltd.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    11/16/2021
    Primary completion :
    02/22/2024
    Completion :
    11/01/2029
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • bireociclib (XZP 3287)
    A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer (NCT05257395)
    Phase 3
    Xuanzhu Biopharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    02/25/2022
    Initiation :
    02/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    letrozole • anastrozole • bireociclib (XZP 3287)